Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.43% | 34.33% | 2,405.06% | 49.08% | 61.40% |
| Total Depreciation and Amortization | 471.43% | 239.73% | -3.95% | 5.63% | 18.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.16% | 79.85% | -177.26% | 184.21% | 25.56% |
| Change in Net Operating Assets | 110.75% | -104.86% | 87.34% | 26.41% | -4,309.09% |
| Cash from Operations | 73.71% | 33.73% | 125.00% | 60.16% | 43.99% |
| Capital Expenditure | 12.12% | 37.60% | 14.95% | 132.88% | -62.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.27% | 13,620.61% | -2,350.20% | 9.34% | -659.45% |
| Cash from Investing | 94.36% | -366.90% | -3,664.79% | 22.55% | -896.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -44.52% | 488.89% | -26.48% | 273.00% | 72.73% |
| Repurchase of Common Stock | -- | 16.95% | 26.87% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -264.47% | 2,021.21% | 26.97% | 112.86% | 72.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 305.64% | -7.87% | -1,047.81% | 421.10% | -63.61% |